智通财经网·2025-11-06 09:20Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tocilizumab Sustained-Release Tablets, which are used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Chinese and Western Medicine Co., Ltd., has been granted a drug registration certificate for Tocilizumab Sustained-Release Tablets [1] - The drug was originally developed by Pfizer and was launched in the United States in 2016 [1] - The company submitted a registration application for the drug to the National Medical Products Administration in January 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 19.42 million in research and development for this drug [1]